Patents - Global Data - Dimensions
Application
Highly potent ISVD compounds capable of substituting for FVIII(a)
Applicants
- Novo Nordisk (Denmark)
[NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
The present invention provides ISVD polypeptide derivatives capable of binding coagulation factor IX(a) and factor Provides half-life. Accordingly, the ISVD polypeptide derivatives disclosed herein are suitable for treating hemophilia A, hemophilia A with inhibitors, and acquired hemophilia A by various routes of administration, including subcutaneous and oral administration.
Patent Family Records (6)
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
Novo Nordisk (Denmark), Novo Nordisk AS VEGGE ANDREAS, STEFFENSEN SOREN, BUYSE MARIE ANGE, (...more)
2024, US-20240067944-A1
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
NOVO NORDISK AS, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, TW-202409091-A
Highly potent ISVD compounds capable of substituting for FVIII(a)
NOVO NORDISK A, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, KR-20240007881-A
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-7459354-B2
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-2024073606-A
Highly Potent ISVD Compounds that Can Replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS ANDREAS VEGGE, SIMONE FULLE, MATHIAS NORRMAN, (...more)
2024, JP-2024020151-A